Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gapper! CEL-SCI Corporation Poping after Optimistic Phase 3 Tests
Read more: http://www.benzinga.com/news/12/01/2280013/cel-sci-corporation-pops-after-optimistic-phase-3-tests#ixzz1kHw4dsr4
CEL-SCI Corporation Popping Strong Pre-Market!
Read more: http://www.benzinga.com/news/12/01/2280013/cel-sci-corporation-pops-after-optimistic-phase-3-tests#ixzz1kHw4dsr4
CEL-SCI Corporation Pops after Optimistic Phase 3 Tests
Read more: http://www.benzinga.com/news/12/01/2280013/cel-sci-corporation-pops-after-optimistic-phase-3-tests#ixzz1kHw4dsr4
AMPE should rocket today after this news-- http://finance.yahoo.com/news/Investigators-Identify-Prime-iw-4161435794.html?x=0
The shorts did a major job on this stock. I hope they all go to jail for market manipulation.
AMPE exploding!
Shorts are covering following report that company is coming after them for publishing bogus news!
Big bounce for AMPE- shorts are covering!
AMPE due for big bounce on news
Shorts will have to cover!
http://finance.yahoo.com/news/Ampio-Responds-Recent-prnews-3517065156.html?x=0
http://finance.yahoo.com/news/Ampio-Responds-What-May-Be-iw-3405933306.html?x=0
FDA approval coming: GTHP up 22% and trying to break 3yr resistance levels. See: http://bit.ly/uzkWGi
GTHP up 22% and trying to break 3yr resistance levels. Could go much higher because FDA approval set to be announced! See: http://bit.ly/uzkWGi
GTHP exploding after report that FDA approval is coming - if it breaks resistance at $1.45 this will fly even higher! http://www.biomedreports.com/2011120985435/chatter-concerning-upcoming-fda-decision.html
GTHP exploding after report that FDA approval is coming - if it breaks resistance at $1.45 this will fly even higher! http://www.biomedreports.com/2011120985435/chatter-concerning-upcoming-fda-decision.html
Report: 3 Stocks that smart money and analysts like which are poised to make a run
http://www.benzinga.com/news/global/11/12/2179448/3-stocks-that-smart-money-and-analysts-like-which-are-poised-to-make-a-tec
Mentions LPTN!
Check out this new report: Set to move- Three micro-cap stocks that analysts and instituional investors like
Along with substantial institutional ownership and solid "buy" recommendations by analysts, the thing that sets this group apart is the fact that they are all micro-cap stocks (with values between $50 and $300 million) that are showing a strong technical possibility of moving out of their recent consolidation trends.
As some of you know, triangle patterns are usually characteristics of a trend consolidation followed by an accelerated break out of the pattern in the direction of the continuing trend.
All of these stocks are showing a symmetrical triangle which is indicative of a period of consolidation during a trend. As such, the pattern yields to a breakout in the direction that corresponds with the trend beforehand. In short, something has to give and if you like to trade, then you may want to put these potential movers on your radar screen.
Lpath Inc (LPTH) is a therapeutic antibody company which has been getting increased attention for its focus on lipid-based therapeutics, which some believe may be the next big thing in biotech.
Unlike the vast majority of developmental biotech companies its size, Lpath benefits from having a powerhouse partnership with Pfizer, the world's largest pharmaceutical firm. Last year, a transformational deal was made in which Lpath was paid an upfront option payment of $14mm, with the potential for a total of $497.5mm in milestones if Pfizer decides to license rights to one of the drugs undergoing clinical trials (iSONEP™) and expecting results soon.
With a current market cap of 63M, the stock has an analyst price target of $8 and is currently 27% lower than its 52-Week high of $1.55. Volume and trading activity has been rising in the stock has been on the rise since October.
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=20128150
Report: Set to move- Three micro-cap stocks that analysts and instituional investors like
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=20128150
Along with substantial institutional ownership and solid "buy" recommendations by analysts, the thing that sets this group apart is the fact that they are all micro-cap stocks (with values between $50 and $300 million) that are showing a strong technical possibility of moving out of their recent consolidation trends.
As some of you know, triangle patterns are usually characteristics of a trend consolidation followed by an accelerated break out of the pattern in the direction of the continuing trend.
All of these stocks are showing a symmetrical triangle which is indicative of a period of consolidation during a trend. As such, the pattern yields to a breakout in the direction that corresponds with the trend beforehand. In short, something has to give and if you like to trade, then you may want to put these potential movers on your radar screen.
Lpath Inc (LPTH) is a therapeutic antibody company which has been getting increased attention for its focus on lipid-based therapeutics, which some believe may be the next big thing in biotech.
Unlike the vast majority of developmental biotech companies its size, Lpath benefits from having a powerhouse partnership with Pfizer, the world's largest pharmaceutical firm. Last year, a transformational deal was made in which Lpath was paid an upfront option payment of $14mm, with the potential for a total of $497.5mm in milestones if Pfizer decides to license rights to one of the drugs undergoing clinical trials (iSONEP™) and expecting results soon.
With a current market cap of 63M, the stock has an analyst price target of $8 and is currently 27% lower than its 52-Week high of $1.55. Volume and trading activity has been rising in the stock has been on the rise since October.
Dr. Bio.. Your take is refreshing.
As the CEO said, this is a defining moment for Integenx.
"Not only is the company worth more by virtue of owning a drug that is fully approved by the FDA, but the market should put a lower discount rate on the probability of success for the other 10 drugs in their pipeline, now that they have taken a drug all the way from development through to FDA approval.
The fact that most of their drugs are on the 505b2 pathway to approval is also very significant because that is a far less capital intensive development path than the traditional PhaseI-II-III path; assuming they can sell or license this newly approved drug to another company, I don't believe they will be forced to raise money again. (Note that Intelgenx's cash balance only declined by $100,000 between June 30, 2011 and September 30, 2011; the financing they did with Rodman Renshaw closed in June, so had nothing to do with the fact cash only went down by $100,000.) "
FCSC? I think not.
Please experts... Do tell.
Have you all even spoken to management at the firm?
Have you read reports from other analysts about the company or do you even the big and very successful funds who are invested in the company? Funds who have placed big bets for the long term- not the pop?
To compare IGXT to that joke of a company FCSC is ridiculous.
Who are the pumpers Patrick?
biomedreports should know. They knew the PDUFA date had been changed before everyone and they interviewed the CEO: http://bit.ly/rAgNpu
Just emailed them. BioMedReports is confirming that it is a full approval.
YEEEEEHAW!!!!!!
Thanks for posting that audio interview with Garza. This technology sounds really promising and its in a space with a great deal of projected growth. Picked up a bunch of shares today.
Penny play making news
Looks like this is going higher based on the reports below.
Ticker: CATSD
http://www.marketwatch.com/story/catasys-ceo-confirms-firms-bullish-growth-projections-2011-09-29
http://finance.yahoo.com/news/Several-Market-Factors-Should-iw-2031890832.html?x=0
CATASYS news
http://tinyurl.com/63ec37q
CATASYS jumped 25% yesterday. More coming!
Ticker is: CATSD
http://www.marketwatch.com/story/catasys-ceo-confirms-firms-bullish-growth-projections-2011-09-29
I agree with you. I think BAPI has a great chance and is the best hope right now against Alzheimers.
I first heard and learned about ILNS by watching this video:
http://vimeo.com/14178112
BMR are amateurs? LMAO!
Those guys move markets and have real juice, especially if they can move stocks in these horrible markets like they have been.
I just made big money with them on ILNS, SVFC (from $3 to $5) and TSPT (from $6.56 to $7.36.) And that was just this week!!
A pump or not, this thing is moving. Someone knows something.
Can't wait to see what is going to happen next!
Thursday's Movers in Healthcare include FDA play Sanuwave
08/25/2011 Shares of Sanuwave Healthcare (OTCBB:SNWV) continue to rise after report speculated that San Antonio based, Kinetic Concepts (NYSE:KCI) might look to acquire Sanuwave for a reasonable price; given the small-cap competitor's current market valuation and the fact Sanuwave's dermaPACE® device for the treatment of diabetic foot ulcers poses a considerable threat to Kinetic's own V.A.C product. KCI generated $1 billion in U.S. revenue in 2010, healing the same types of wounds that dermaPACE® treated patients with during recently completed double-blind clinical studies. Sanuwave is on the clock for an FDA approval decision and expects to begin marketing dermaPACE® in 2012.
Sanuwave uses a promising technology which utilizes high-energy acoustic pressure waves in the "shock wave" spectrum to elicit biological effects and induce tissue regeneration and healing. Chronic and complex wounds, especially those seen in diabetic patients cost patients over $20 billion annually in the U.S. alone.
Physicians have noted that the Georgia based firm's treatment technology is non-invasive and devoid of significant clinical side effects. That has industry insiders and Wall Street commentators reasoning that the FDA approval for the acoustic pressure wave treatment device could exponentially increase the value of the firm.
Shares of California based Cutera, Inc. (Nasdaq:CUTR) rose in early trading after it was announced today that Kevin Connors, the Company's President and CEO, will be presenting at the Wedbush Securities 2011 Life Sciences Management Access Conference to be held on August 16-17, 2011 at Le Parker Meridien in NYC. Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, and a recent earning report filed by the firm indicated that second quarter 2011 revenue was $14.9 million, or 22% higher, when compared to $12.2 million in the same period last year. Net loss for the second quarter of 2011 was $2.5 million or $0.18 per diluted share, compared to a net loss of $3.8 million or $0.28 per diluted share.
Shares of Vanda Pharmaceuticals Inc (Nasdaq:VNDA) also traded higher by $0.20, pushing the share price to $5.53 in early trading. Stock volume in Vanda Pharmaceuticals Inc has returned as the stock continues to recover after they saw a 52-week high of $10.32. Current prices see shares trading -46% lower, but attempting to bounce off 52-week lows on low volume. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. In recent weeks, the company has announced various exclusive license agreements to export Fanapt™ (iloperidone); a medications for schizophrenia known as an atypical antipsychotic. The term "atypical" refers to the different mechanisms of action of second-generation antipsychotics.
Report: Thursday's Movers in Healthcare include Sanuwave
08/25/2011 Shares of Sanuwave Healthcare (OTCBB:SNWV) continue to rise after report speculated that San Antonio based, Kinetic Concepts (NYSE:KCI) might look to acquire Sanuwave for a reasonable price; given the small-cap competitor's current market valuation and the fact Sanuwave's dermaPACE® device for the treatment of diabetic foot ulcers poses a considerable threat to Kinetic's own V.A.C product. KCI generated $1 billion in U.S. revenue in 2010, healing the same types of wounds that dermaPACE® treated patients with during recently completed double-blind clinical studies. Sanuwave is on the clock for an FDA approval decision and expects to begin marketing dermaPACE® in 2012.
Sanuwave uses a promising technology which utilizes high-energy acoustic pressure waves in the "shock wave" spectrum to elicit biological effects and induce tissue regeneration and healing. Chronic and complex wounds, especially those seen in diabetic patients cost patients over $20 billion annually in the U.S. alone.
Physicians have noted that the Georgia based firm's treatment technology is non-invasive and devoid of significant clinical side effects. That has industry insiders and Wall Street commentators reasoning that the FDA approval for the acoustic pressure wave treatment device could exponentially increase the value of the firm.
Shares of California based Cutera, Inc. (Nasdaq:CUTR) rose in early trading after it was announced today that Kevin Connors, the Company's President and CEO, will be presenting at the Wedbush Securities 2011 Life Sciences Management Access Conference to be held on August 16-17, 2011 at Le Parker Meridien in NYC. Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, and a recent earning report filed by the firm indicated that second quarter 2011 revenue was $14.9 million, or 22% higher, when compared to $12.2 million in the same period last year. Net loss for the second quarter of 2011 was $2.5 million or $0.18 per diluted share, compared to a net loss of $3.8 million or $0.28 per diluted share.
Shares of Vanda Pharmaceuticals Inc (Nasdaq:VNDA) also traded higher by $0.20, pushing the share price to $5.53 in early trading. Stock volume in Vanda Pharmaceuticals Inc has returned as the stock continues to recover after they saw a 52-week high of $10.32. Current prices see shares trading -46% lower, but attempting to bounce off 52-week lows on low volume. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. In recent weeks, the company has announced various exclusive license agreements to export Fanapt™ (iloperidone); a medications for schizophrenia known as an atypical antipsychotic. The term "atypical" refers to the different mechanisms of action of second-generation antipsychotics.
This one starting to break out on positive news coverage. Upcoming FDA approval. Check out the last two articles:
http://seekingalpha.com/article/289566-smart-buyers-slowly-returning-to-fda-decision-plays
http://biomedreports.com/2011082272417/disruptive-technology-with-multi-market-applications-up-for-fda-approval.html
There is a new article about these guys on Seeking Alpha that mentions these guys as buyout candidates upon approval from the FDA--
http://tinyurl.com/3r7te9a
SNWV a buyout candidate on FDA approval.. SEE: http://seekingalpha.com/article/289566-smart-buyers-slowly-returning-to-fda-decision-plays
Marketwatch article mentions IMUC as one of the best cancer vaccine stocks to buy. This is an important endorsement! Read it at the link below. Titled "Placing The Right Bet on Cancer Vaccines' Horses"
http://www.marketwatch.com/story/placing-the-right-bet-on-cancer-vaccines-horses-2011-08-16?reflink=MW_news_stmp
Marketwatch just published a fantastic article on IMUC! Read it here: http://www.marketwatch.com/story/placing-the-right-bet-on-cancer-vaccines-horses-2011-08-16?reflink=MW_news_stmp
I spoke to them and they are not doing a write up. However, they did do a write up last year:
http://biomedreports.com/2010040434445/right-place-right-time-for-this-new-food-safety-technology.html
And I also found this video:
China's rare earth restrictions could lead to supply shortage
http://www.mineweb.com/mineweb/view/mineweb/en/page72068?oid=124438&sn=Detail&pid=102055
Garza says the company is not being investigated at all. They halted the trading to investigate thestreet and Mayo's statements. Trading should resume after company issues news statement according to Amex sources. I guess we'll see who is full of it tomorrow.
Also, he says investors may have a claim against TheStreet and/or Mayo:
http://twitter.com/#!/search/%24RPC
Garza tweeted about RPC. Feuertstein silent!
http://bit.ly/fDzRNX